Please login to the form below

Not currently logged in
Email:
Password:

Synairgen

This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.

AZ severe asthma drug benralizumab backed by CHMP

AZ severe asthma drug benralizumab backed by CHMP

Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

Latest news

  • AZ trial adds to pessimism about anti-IL-13 asthma drugs AZ trial adds to pessimism about anti-IL-13 asthma drugs

    Last year AZ's respiratory pipeline took a further knock when it halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma after deciding it

  • Synairgen sinks as AZ halts trial of asthma drug Synairgen sinks as AZ halts trial of asthma drug

    AZD9412 is an inhaled form of interferon beta partnered with UK company Synairgen, which saw its London Stock Exchange-listed shares lose more than a third of their value yesterday when ... For Synairgen, the setback lends greater importance to its

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    Boosts respiratory portfolio with $232m deal. AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in trials to ... AZ is paying UK-based Synairgen $7.25m

  • Pharma continues to attract investors

    Synairgen raises fresh cash for asthma and pulmonary disease research. Synairgen, the drug research company, rose just over 1p to 19p following a share placing at 17p to raise £6.35m – ... The cash produced by the discounted placing is to go towards

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics